IDEAYA Biosciences, Inc.
Ideaya Biosciences (Nasdaq: IDYA) is a precision medicine oncology company that discovers and develops therapies for genetically defined cancers, focusing on small-molecule drugs and antibody-drug conjugates for solid tumors. Its clinical pipeline includes nine product candidates across four focus areas: uveal… From the company’s description.
Over the twelve months to Sep 30, 2026, IDEAYA Biosciences, Inc. reported revenue of $36.54M, down 83.0% from a year earlier, and a net loss of $420.01M. Operations used $347.36M in cash. In fiscal 2025, it reported revenue of $218.71M, up 3024.4% from fiscal 2024, and a net loss of $113.70M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What IDEAYA Biosciences, Inc. does
In the company’s own words
Ideaya Biosciences (Nasdaq: IDYA) is a precision medicine oncology company that discovers and develops therapies for genetically defined cancers, focusing on small-molecule drugs and antibody-drug conjugates for solid tumors. Its clinical pipeline includes nine product candidates across four focus areas: uveal melanoma, ADC and DNA damage response combinations, MTAP-pathway cancers, and next-generation therapies. The company’s programs include darovasertib, a PKC inhibitor being studied for uveal melanoma; IDE849, a DLL3-targeting ADC; IDE161, a PARG inhibitor; and IDE397, a MAT2A inhibitor. It develops therapies for use alone or in rational combinations and works with pharmaceutical and diagnostic partners on clinical development and patient selection. Ideaya also operates a research platform for target and biomarker discovery, drug design, and translational biology, supported by proprietary chemical and genetic-screening resources. The company has no products approved for commercial sale and reports its business as a single operating segment. Its principal corporate website is www.ideayabio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1676725
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns IDEAYA Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · IDEAYA Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do IDEAYA Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of IDEAYA Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in IDEAYA Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”